SG11201807725WA - Methods of diagnosing cancer - Google Patents

Methods of diagnosing cancer

Info

Publication number
SG11201807725WA
SG11201807725WA SG11201807725WA SG11201807725WA SG11201807725WA SG 11201807725W A SG11201807725W A SG 11201807725WA SG 11201807725W A SG11201807725W A SG 11201807725WA SG 11201807725W A SG11201807725W A SG 11201807725WA SG 11201807725W A SG11201807725W A SG 11201807725WA
Authority
SG
Singapore
Prior art keywords
singapore
bcaa
international
methods
pct
Prior art date
Application number
SG11201807725WA
Inventor
Weiping Han
Russell E Ericksen
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201807725WA publication Critical patent/SG11201807725WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111101110011111111111111101111011111 International Bureau ... ..... ..)d (10) International Publication Number ..... ......!::, (43) International Publication Date WO 2017/155467 Al 14 September 2017 (14.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/216 (2006.01) GO1N 33/574 (2006.01) kind of national protection available): AE, AG, AL, AM, A61P 35/00 (2006.01) C12Q 1/32 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A23L 33/175 (2016.01) A61P 3/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, G01N 33/68 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/SG2017/050112 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 8 March 2017 (08.03.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 10201601791W 8 March 2016 (08.03.2016) SG GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Connexis North Tower, Singapore 138632 (SG). (72) Inventors: HAN, Weiping; Consortium (SBIC), Biomedical LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, c/o Singapore Bioimaging GW, KM, ML, MR, NE, SN, TD, TG). Sciences Institutes, 11 Bi- opolis Way, #02-02 Helios, Singapore 138667 (SG). ER- Declarations under Rule 4.17: Bioimaging Consorti- ICKSEN, Russell E.; c/o Singapore - of inventorship (Rule 4.17(N)) Institutes, 11 Biopolis um (SBIC), Biomedical Sciences 138667 (SG). Published: Way, #02-02 Helios, Singapore (ASIA) PTE LTD; — with international search report (Art. 21(3)) (74) Agent: SPRUSON & FERGUSON P.O. Box 1531, Robinson Road Post Office, Singapore with sequence listing part of description (Rule 5.2(a)) 903031 (SG). CANCER (54) Title: METHODS OF DIAGNOSING NoQtumor ECG 2.0- TUMOT BCA.AS 2-0 - os ... t LFD m — .$ 4o L HFO+BC.kA 1-1 .4 IN Figure 4 ii- ir) ir) (57) : Disclosed are two methods of treating or preventing a proliferative disease as characterized and/or diagnosed by at Il ----. least one selected from an accumulation of branched-chain amino acid (s) (BCAA), suppression of activity or transcripts level of N BCAA catabolic enzyme(s) and a decrease in acylcarnitine level (C5:1 ), one comprising the administration of a BCAA catabolism C enhancer and/or branched chain alpha-ketoacid dehydrogenase complex (BCKDC) kinase inhibitor and the other comprising admin - el istration of a meal replacement with low BCAA levels. In three separate embodiments, methods of diagnosis or prognosis are dis - O closed, each comprising the measurement of the levels of a different marker, i.e. BCAA, BCAA catabolic enzymes or acylcarnitine (C5:1 ). In preferred embodiments, the proliferative disease is cancer. Also disclosed is a kit or microarray chip useful for methods 5- thereof.
SG11201807725WA 2016-03-08 2017-03-08 Methods of diagnosing cancer SG11201807725WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201601791W 2016-03-08
PCT/SG2017/050112 WO2017155467A1 (en) 2016-03-08 2017-03-08 Methods of diagnosing cancer

Publications (1)

Publication Number Publication Date
SG11201807725WA true SG11201807725WA (en) 2018-10-30

Family

ID=59789584

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201807725WA SG11201807725WA (en) 2016-03-08 2017-03-08 Methods of diagnosing cancer
SG10201913528PA SG10201913528PA (en) 2016-03-08 2017-03-08 Methods of diagnosing cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913528PA SG10201913528PA (en) 2016-03-08 2017-03-08 Methods of diagnosing cancer

Country Status (4)

Country Link
US (1) US20190083436A1 (en)
EP (1) EP3426241A4 (en)
SG (2) SG11201807725WA (en)
WO (1) WO2017155467A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108498798A (en) * 2018-04-17 2018-09-07 上海市第六人民医院 It is a kind of prevention skeletal muscle atrophy medicine target spot and its application
CN111363826A (en) * 2020-04-29 2020-07-03 徐州医科大学 New use of PCCA gene in diagnosis and treatment of renal cancer
EP4232164A1 (en) * 2020-10-20 2023-08-30 Baylor College of Medicine Multiplex metabolic markers in plasma for early detection of african american prostrate cancer
CN114414806A (en) * 2022-02-07 2022-04-29 河南中医药大学第一附属医院 Marker for diagnosing gallbladder cancer and application thereof
CN116359272B (en) * 2023-04-03 2023-11-10 汕头大学医学院 Metabolic marker and application thereof in diagnosis and prediction of esophageal cancer
CN117388495B (en) * 2023-12-13 2024-02-09 哈尔滨脉图精准技术有限公司 Application of metabolic marker for diagnosing lung cancer stage and kit

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923257B2 (en) * 2007-05-04 2011-04-12 Perkinelmer Health Sciences, Inc. Detecting isomers using differential derivatization mass spectrometry
ES2799327T3 (en) * 2009-05-05 2020-12-16 Infandx Ag Method to diagnose suffocation
EP3307870B1 (en) * 2015-06-10 2023-08-02 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid

Also Published As

Publication number Publication date
EP3426241A1 (en) 2019-01-16
WO2017155467A1 (en) 2017-09-14
SG10201913528PA (en) 2020-02-27
US20190083436A1 (en) 2019-03-21
EP3426241A4 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
SG11201807725WA (en) Methods of diagnosing cancer
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201807972YA (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201408261UA (en) Syringe
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809605PA (en) Compositions for and method of treating acid-base disorders
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201908743SA (en) Methods and compositions for modulation of immune cells
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201807501UA (en) Method and system for imaging
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201909837YA (en) Methods for treating lung disorders
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201806945SA (en) Cancer epigenetic profiling
SG11201809996QA (en) Ribonucleic acid (rna) interactions
SG11201408171SA (en) Fbxo3 inhibitors
SG11201903420SA (en) Antisense oligonucleotides